CA Patent

CA2301586A1 — Method for treatment of non-rheumatoid arthritis

Assigned to Eli Lilly and Co · Expires 1999-03-04 · 27y expired

What this patent protects

A method is disclosed for the treatment of non-rheumatoid arthritis by administering to a mammal in need thereof a therapeutically effective amount of an sPLA2 inhibitor.

USPTO Abstract

A method is disclosed for the treatment of non-rheumatoid arthritis by administering to a mammal in need thereof a therapeutically effective amount of an sPLA2 inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
CA2301586A1
Jurisdiction
CA
Classification
—
Expires
1999-03-04
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.